TipRanks
Hospital Corporation of China Ltd (HK:3869)
:3869
Hong Kong Market
Want to see HK:3869 full AI Analyst Report?

Hospital Corporation of China Ltd (3869) AI Stock Analysis

1 Followers

Top Page

HK:3869

Hospital Corporation of China Ltd

(3869)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - Gpt-5.6Sol)
Rating:50Neutral
Price Target:
HK$3.50
▲(2.94% Upside)
Action:Reiterated
Date:10/03/26
The score is held back primarily by balance-sheet leverage and weak technical positioning (price below key moving averages with negative MACD). Financial performance provides partial offset due to the strong 2025 revenue rebound and return to profitability with positive free cash flow, but valuation is unattractive/unclear given the negative P/E and no dividend yield data.
Positive Factors
Revenue and Profit Recovery
The sharp 2025 revenue rebound and return to profitability indicate renewed demand for the company’s healthcare services and improved operating execution. If sustained, stronger volumes and earnings can support reinvestment, improve financial resilience, and strengthen the hospital network’s ability to compound results.
Negative Factors
High Balance-Sheet Leverage
Debt remains substantial relative to shareholders’ equity, so weaker patient activity, margins, or cash generation could place greater pressure on financial flexibility. Elevated leverage may also restrict the company’s ability to fund expansion internally and makes sustained operating improvement important for balance-sheet stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profit Recovery
The sharp 2025 revenue rebound and return to profitability indicate renewed demand for the company’s healthcare services and improved operating execution. If sustained, stronger volumes and earnings can support reinvestment, improve financial resilience, and strengthen the hospital network’s ability to compound results.
Read all positive factors

Hospital Corporation of China Ltd (3869) vs. iShares MSCI Hong Kong ETF (EWH)

Hospital Corporation of China Ltd Business Overview & Revenue Model

Company Description
Hospital Corporation of China Limited, an investment holding enterprise, primarily focuses on the administration and direct management of hospitals across the People's Republic of China. The company extends specialized management and consulting se...
How the Company Makes Money
Hospital Corporation of China Ltd primarily generates revenue by providing medical and healthcare services to patients through its operated medical institutions. Key revenue streams typically include fees for outpatient consultations, inpatient se...

Hospital Corporation of China Ltd Financial Statement Overview

Summary
Operating results improved sharply in 2025 with revenue up 35.3% and a return to profitability (~9.3% net margin) after a 2024 loss, supported by consistently positive free cash flow. However, balance-sheet risk remains a meaningful drag: leverage is still high (debt-to-equity ~2.10x in 2025) and operating cash flow is modest relative to the debt load, limiting near-term self-deleveraging capacity. Profitability also shows year-to-year volatility versus the stronger 2023 margin profile.
Income Statement
66
Positive
Balance Sheet
48
Neutral
Cash Flow
58
Neutral
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.47B1.44B1.43B1.14B520.29M
Gross Profit267.62M275.82M239.36M150.88M214.23M
EBITDA183.01M243.34M283.48M-464.44M-401.87M
Net Income136.42M-38.63M131.38M-480.95M-280.71M
Balance Sheet
Total Assets2.58B2.58B2.50B2.44B3.12B
Cash, Cash Equivalents and Short-Term Investments805.00M813.08M667.89M627.61M779.97M
Total Debt1.06B1.15B1.04B1.10B1.09B
Total Liabilities1.86B2.01B1.91B1.99B1.99B
Stockholders Equity502.72M337.71M379.09M255.71M797.97M
Cash Flow
Free Cash Flow137.27M196.87M67.40M126.49M117.27M
Operating Cash Flow158.92M212.07M82.69M143.13M133.07M
Investing Cash Flow-107.87M42.64M-15.52M187.16M13.96M
Financing Cash Flow-98.00M-64.00M-41.62M-279.34M-550.82M

Hospital Corporation of China Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.40
Price Trends
50DMA
3.40
Negative
100DMA
3.40
Negative
200DMA
4.01
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
0.21
Positive
STOCH
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3869, the sentiment is Negative. The current price of 3.4 is above the 20-day moving average (MA) of 3.39, above the 50-day MA of 3.40, and below the 200-day MA of 4.01, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 0.21 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3869.

Hospital Corporation of China Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$595.22M5.746.35%10.11%-0.27%29.73%
62
Neutral
HK$5.79B27.952.55%0.39%1.59%-58.55%
56
Neutral
HK$1.10B77.620.48%1.10%-3.26%―
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
HK$936.00M23.505.59%―――
50
Neutral
HK$467.79M-144.57-0.41%―3.16%-101.02%
44
Neutral
HK$572.07M-3.03-8.65%―47.93%65.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:3869
Hospital Corporation of China Ltd
3.39
-3.37
-49.85%
HK:9906
Honliv Healthcare Management Group Co Ltd
1.56
0.06
4.00%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
1.88
0.13
7.55%
HK:3886
Town Health International Medical Group Ltd.
0.16
-0.13
-45.12%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
9.49
-4.32
-31.28%
HK:2453
Concord Healthcare Group Co., Ltd. Class H
0.70
-2.22
-76.03%

Hospital Corporation of China Ltd Corporate Events

Hospital Corporation of China Reshapes Board to Bolster Governance and Compliance
Sep 22, 2026
Hospital Corporation of China Limited is a Hong Kong-listed healthcare group that operates and invests in hospital and medical services businesses in China, supported by institutional capital and experienced board members. The company’s gove...
Hospital Corporation of China Updates Board and Committee Structure
Sep 22, 2026
Hospital Corporation of China Limited has announced the latest composition of its board of directors, detailing the roles of executive, non-executive and independent non-executive members. The board continues to be chaired by executive director Ca...
Hospital Corporation of China Posts Strong Adjusted Profit Despite Flat Revenue
Aug 25, 2026
Hospital Corporation of China Limited reported unaudited interim results for the six months ended 30 June 2026, showing relatively stable revenue at RMB732.8 million versus RMB743.0 million a year earlier. General hospital services continued to ac...
Hospital Corporation of China Sets Board Meeting to Review Interim Results and Dividend
Aug 13, 2026
Hospital Corporation of China Limited has scheduled a board meeting for 25 August 2026 to review and approve the group’s unaudited interim results for the six months ended 30 June 2026. The board will also consider the possible declaration o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2026